Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.
Eyre TA, Martinez-Calle N, Paneesha S, Norouzi M, Tucker D, Walter H, Boden A, Kilner M, Phillips N, Patten PEM, Shah N, Ruparelia M, Oddy S, Tsawayo T, Forconi F, Wardle H, Gbemre T, Gregory C, Cook L, Allsup D, Morris A, Knechtli C, Davies J, Galani J, Marr H, Hutchinson C, Williams S, Hickey J, Harding H, Hunjan S, Blak BT, Walewska R.
Eyre TA, et al.
Blood Adv. 2026 Jul 28;10(14):4873-4883. doi: 10.1182/bloodadvances.2026019978.
Blood Adv. 2026.
PMID: 42054544
Free PMC article.